Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 6Neoplasms 4Myelodysplastic Syndromes 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 2Recurrence 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Stable Colorectal Carcinoma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 29Cyclophosphamide 26Whole-Body Irradiation 21Cyclosporine 20Busulfan 20Mycophenolic Acid 19Tacrolimus 16Antilymphocyte Serum 14Methotrexate 13romidepsin 12Etoposide 12Filgrastim 11Melphalan 9Psychiatric Rehabilitation 8Methylprednisolone 8Dexamethasone 8Bexarotene 8Vorinostat 7Flow Cytometry 7Therapeutics 6Radiotherapy 6Calcium Dobesilate 6Brentuximab Vedotin 6Bortezomib 6Alemtuzumab 6sargramostim 5fludarabine 5denileukin diftitox 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Cutaneous × cc-486 × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡